ERBB2 and breast carcinoma: Therefore, it is a reasonable attempt to assign a score of 0 to either the HER2-low tumor or the HER2-positive tumor treated with targeted therapy, and 1 to HER2-zero breast cancers in the mNeo-Bioscore system.